Safety of repeated low-level red-light therapy for myopia: A systematic review
Asia-Pacific Journal of Ophthalmology · 2024-11 · 13 (6) · 100124
DOI: 10.1016/j.apjo.2024.100124 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Asia-Pacific Journal of Ophthalmology, 2024-11. Verfasst von Yanping Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and …. Hauptthemen laut MEDLINE: Myopia, Visual Acuity. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
PURPOSE: Establishing the safety profile of repeated low-level red-light (RLRL) therapy is necessary prior to its widespread clinical implementation. METHODS: We conducted a systematic review (International Prospective Register of Systematic Reviews, CRD42024516676) of articles across seven databases from inception through February 10, 2024, with keywords related to myopia and RLRL therapy. Pooled safety outcomes and risk-to-benefit ratios were reported, and incidence of side effects was compared with other antimyopia interventions. RESULTS: Among 689 screened articles, 20 studies (2.90 %; median duration 9 months, longest 24 months) were analysed, encompassing 2380 participants aged 3-18 years and 1436 individuals undergoing RLRL therapy. Two case reports described an identical patient with reversible decline in visual acuity and optical coherence tomography (OCT) abnormalities, completely resolved 4 months after treatment cessation. No cases of permanent vision loss were reported. Temporary afterimage was the most common ocular symptom following treatment, resolving within 6 minutes in reported studies. The number needed to harm outweighed the number needed to treat by a ratio of 12.7-21.4 for a person with -3D to -8D myopia treated with RLRL therapy. Incidence of side effects from RLRL was 0.088 per 100 patient-years (95 % confidence interval, 0.02-0.50). CONCLUSIONS: No irreversible visual function loss or ocular structural damage was identified with RLRL. Fundus photography and OCT before and during therapy, alongside home monitoring of visual acuity and duration of afterimages, are necessary to identify side effects. Further adequately powered studies of longer duration are needed to evaluate long-term safety of RLRL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocul…
- Department of Clinical Research, Shanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai Vision Health Center and Shanghai Children Myopia Institute, Shanghai, China; Shanghai Engineering C…
- Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia; Research Centre for SHARP Vision (RCSV), The Hong Kong Polytechnic University, Kowloon, Hong Kong, China. Electronic ad…
Zitieren
APA
Chen, Y., Xiong, R., Yang, S., Zhu, Z., Li, H., Xiang, K., Congdon, N., Wang, W., & He, M. (2024). Safety of repeated low-level red-light therapy for myopia: A systematic review. Asia-Pacific Journal of Ophthalmology, 13(6), 100124. https://doi.org/10.1016/j.apjo.2024.100124
Vancouver
Chen Y, Xiong R, Yang S, Zhu Z, Li H, Xiang K, et al. Safety of repeated low-level red-light therapy for myopia: A systematic review. Asia-Pacific Journal of Ophthalmology. 2024;13(6):100124. doi:10.1016/j.apjo.2024.100124
BibTeX
@article{Chen2024,
author = {Chen, Yanping and Xiong, Ruilin and Yang, Shaopeng and Zhu, Ziyu and Li, Huangdong and Xiang, Kaidi and Congdon, Nathan and Wang, Wei and He, Mingguang},
title = {Safety of repeated low-level red-light therapy for myopia: A systematic review},
journal = {Asia-Pacific Journal of Ophthalmology},
year = {2024},
volume = {13},
number = {6},
pages = {100124},
doi = {10.1016/j.apjo.2024.100124}
}
EUVIMED